Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients Greater Than Or Equal To Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study

Trial Profile

Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients Greater Than Or Equal To Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Tositumomab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Sep 2015 Planned End Date changed from 1 May 2010 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top